Navigate to
-
Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...
-
Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...
-
Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...
-
Findings also show improved persistence with high-potency, obesity-approved GLP-1 products
Prime Article: Press Releases -
Real-world study of GLP-1 patients continues to deliver leading insights
Prime Article: Press Releases -
Manufacturer: Ferring / Seikagaku Proposed indications Radicular leg pain associated with lumbar disc herniation (LDH) Clinical overview Mechanism of action Condoliase, also known as chondroitin...
-
Manufacturer: Abeona Proposed indications Recessive dystrophic epidermolysis bullosa (RDEB) Clinical overview Mechanism of action Prademagene zamikeracel (pz-cel) is an autologous, collagen type...
-
Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...
Prime Article: Research & Publications -
Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes
Prime Article: Perspectives -
cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...
Prime Article: Research & Publications